Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for
Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Gastroenterology and Liver Disease Research Center, Research Institute for Gastroenterology and Liver Diseases,
Shahid Beheshti University of Medical Sciences, Tehran, Iran
Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for
Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Gastroenterology and Liver Disease Research Center, Research Institute for Gastroenterology and Liver Diseases,
Shahid Beheshti University of Medical Sciences, Tehran, Iran
*Corresponding Address:
P.O.Box
19857-17411
Gastroenterology and Liver Disease Research Center
Research
Institute for Gastroenterology and Liver Diseases
Shahid Beheshti University of Medical Sciences
Yeman St
Chamran Expressway
Tehran
Iran
Email:Nazemalhosseini@sbmu.ac.ir
Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited
This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Larki Pegah,
Gharib Ehsan,
Yaghoob Taleghani Mohammad,
Khorshidi Fatemeh,
Nazemalhosseini-Mojarad Ehsan,
Asadzadeh Aghdaei Hamid.
Coexistence of KRAS and BRAF Mutations in Colorectal
Cancer: A Case Report Supporting The Concept of
Tumoral Heterogeneity.
Cell J.
2017;
19(Suppl 1): 113-117.
The detection of KRAS and BRAF mutations is a crucial step for the correct therapeutic
approach and predicting the epidermal growth factor receptor (EGFR)-targeted therapy
resistance of colorectal carcinomas. The concomitant KRAS and BRAF mutations occur
rarely in the colorectal cancers (CRCs) with the prevalence of less than 0.001% of the cases.
In patients with KRAS-mutant tumors, BRAF mutations should not regularly be tested
unless the patient is participating in a clinical trial enriching for the presence of KRAS or
BRAF-mutated tumor. The current report demonstrates a case with advanced adenocarcinoma
of the colon showing the coexistence of KRAS and BRAF mutations and may have
profound clinical implications for disease progression and therapeutic responses.
